Oscar Health (NYSE:OSCR) CAO Sells 958 Shares

Key Points

• Oscar Health CAO Victoria Baltrus sold 958 shares at an average price of $31.45, totaling $30,129.10. The Rule 10b5-1 transaction covered tax withholding tied to vested equity awards, leaving her with 213,631 shares.
• Oscar Health reported strong quarterly results, posting $1.10 EPS versus the $0.40 consensus and $4.88 billion in revenue, up 70.4% year over year.
• OSCR recently traded at $32.90, near its 52-week high of $33.55, while analysts maintained a consensus “Hold” rating with an average price target of $26.22.

Oscar Health, Inc. (NYSE:OSCR - Get Free Report) CAO Victoria Baltrus sold 958 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total transaction of $30,129.10. Following the completion of the sale, the chief accounting officer directly owned 213,631 shares of the company's stock, valued at $6,718,694.95. This represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oscar Health Price Performance

NYSE:OSCR traded up $0.65 during trading hours on Tuesday, hitting $32.90. 4,754,860 shares of the stock traded hands, compared to its average volume of 7,062,275. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.21. Oscar Health, Inc. has a 1 year low of $10.69 and a 1 year high of $33.55. The company has a market cap of $10.15 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 0.66 and a beta of 2.37. The stock has a 50 day moving average price of $30.49 and a 200 day moving average price of $22.87.

Oscar Health (NYSE:OSCR - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.40 by $0.70. The firm had revenue of $4.88 billion during the quarter, compared to analysts' expectations of $4.73 billion. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The company's revenue for the quarter was up 70.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.89) earnings per share. Sell-side analysts forecast that Oscar Health, Inc. will post 1.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Oscar Health

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in Oscar Health by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 4,798,313 shares of the company's stock valued at $68,964,000 after buying an additional 116,430 shares during the last quarter. BIT Capital GmbH raised its holdings in shares of Oscar Health by 545.0% during the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company's stock worth $88,897,000 after acquiring an additional 5,227,152 shares in the last quarter. Simplify Asset Management Inc. bought a new position in shares of Oscar Health during the 4th quarter valued at approximately $2,948,000. Fortis Group Advisors LLC boosted its position in shares of Oscar Health by 82.9% during the 4th quarter. Fortis Group Advisors LLC now owns 189,857 shares of the company's stock valued at $2,724,000 after acquiring an additional 86,035 shares during the last quarter. Finally, Convergence Investment Partners LLC bought a new stake in Oscar Health in the first quarter worth $1,208,000. 75.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on OSCR. Zacks Research upgraded Oscar Health from a "hold" rating to a "strong-buy" rating in a research report on Monday, July 6th. Robert W. Baird set a $27.00 target price on Oscar Health in a research report on Friday, August 7th. UBS Group lifted their target price on Oscar Health from $20.00 to $26.00 and gave the company a "neutral" rating in a research note on Friday, August 7th. Wall Street Zen upgraded Oscar Health from a "buy" rating to a "strong-buy" rating in a research note on Sunday, June 14th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $30.00 price objective on shares of Oscar Health in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $26.22.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company's primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.